contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nextcell-pharma-ab-nextcell-publishes-its-interim-report-2-20222023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.

NextCell Pharma

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 - February 28, 2023 The report is available on the company's website: https://www...

<div class="abstract">NextCell Pharma AB (publ) (NXTCL or NextCell) publishes&nbsp;its Interim Report 2&nbsp;for the period December 1, 2022&nbsp;- February 28, 2023&nbsp;The report is available on the company's website:&nbsp; <a href="https://www.nextcellpharma.com/en/investors#financial-report">https://www.nextcellpharma.com/en/investors#financial-report</a>. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL".&nbsp;The amount in brackets refers to the corresponding&nbsp;period in the previous year. &nbsp;</div>Second quarter (2022-12-01 until 2023-02-28)<ul><li>Operating income amounted to 2,734 (1,840) TSEK, of which Cellaviva counted for 2,106 (1,279) TSEK.</li></ul>&nbsp;<ul><li>Operating result amounted to -11,408 (-10,212) TSEK.</li></ul>&nbsp;<ul><li>Earnings per share* amounted to -0.33 (-0.30) SEK.</li></ul>&nbsp;<ul><li>Cash and bank amounted to 77,617 (118,170) TSEK.</li></ul>&nbsp;<ul><li>Solidity** amounted to 89.3 (92.7) %</li></ul>First half year (2022-09-01 until 2023-02-28)<ul><li>Operating income amounted to 5,747 (3,187) TSEK of which Cellaviva counted for 4,244 (2,616) TSEK.</li></ul>&nbsp;<ul><li>Operating result amounted to -20,327 (-16,684) TSEK.</li></ul>&nbsp;<ul><li>Earnings per share* amounted to -0.59 (-0.49) SEK.</li></ul>*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2022/2023: 34,379,523 (34,379,523) &nbsp;shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (34,379,523) shares. **Solidity: Own capital's share of the sheet total.Significant events in the second quarter<ul><li>NextCell announced at the end of March that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in the phase II part of the childhood diabetes study.</li><li>The company announced in mid-January that it had received positive comments and recommendations on the draft pediatric plan (PIP) previously submitted to the European Medicines Agency's pediatric unit (PDCO).</li><li>NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by flu, RS and HMP virus.</li></ul>Significant events after the reporting period<ul><li>NextCell announced at the end of March that the results of the clinical phase I/II study in type 1 diabetes had been accepted for publication in the peer-reviewed journal Diabetologia, the official journal of the European Association for the Study of Diabetes</li><li>The company announced late April that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia.</li></ul>This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-04-2023 07:30 CET.